je.st
news
Home
› Agenus Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation
Agenus Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation
2014-07-02 10:39:34| drugdiscoveryonline Home Page
Agenus Inc. an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, recently announced promising Phase 2 results for HerpV, a synthetic vaccine candidate for the treatment of patients with genital Herpes Simplex Virus-2 (HSV-2)
Tags: shows
significant
generated
reduction
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||